A role for the SDF1α/CXCR4 signaling pathway in the development or maintenance of the GBM neovasculature is suggested by a report that demonstrated that the administration of a CXCR4 antagonist to an orthotopic xenograft mouse model of GBM inhibited tumor growth [47]. This evidence concerns the gene CXCL12 and glioblastoma.